


Supplemental Figure 1


A

Pre-treatment



B

Post-progression



Supplemental Figure 1: LOH at chromosome 12p in post-treatment sample. A). Germline allelic fractions (top), copy numbers (log₂ ratio, normalized with matched blood sample, middle) and maximum likelihood tumor copy numbers (bottom) for all heterozygous germline variants in the pre-treatment sample on chromosome 12. Chromosome 12 is diploid with no evidence of LOH. B) The same plot for the post treatment sample. LOH at chr12:10,074,776-18,800,953 supported by both copy number and germline allelic fractions. In the LOH region, germline allelic fractions of about 0.22 represent variants lost in tumor and which are present in the normal contamination only; variants with allelic fraction of about 0.78 are present in tumor and normal.

Supplemental Table 1

Block	KI-67	pMAPK				pEGFR				pMEK			
	% positive	1+	2+	3+	H-score	1+	2+	3+	H-score	1+	2+	3+	H-score
Pre-treatment	13%	20%	5%	0%	35	0%	0%	0%	0	50%	0%	0%	50
Post-progression	16%	10%	20%	0%	50	30%	0%	0%	30	70%	0%	0%	70

Block ID#	pAKT				pS6-235/236				pS6-240/244			
	1+	2+	3+	H-score	1+	2+	3+	H-score	1+	2+	3+	H-score
Pre-treatment	0%	0%	0%	0	40%	0%	0%	40	20%	30%	20%	140
Post-progression	5%	5%	0%	15	10%	0%	0%	10	30%	10%	30%	140

Block ID#	PTEN				ER		PR	
	1+	2+	3+	H-score	Status	AQUA Score	Status	AQUA Score
Pre-treatment	70%	30%	0%	130	Positive	31	Positive	271
Post-progression	80%	0%	0%	80	Positive	312	Positive	1305



Supplemental Table 1. Immunohistochemical analysis of tumor samples.

Supplemental Figure 2



Pre-treatment

Post-progression



ER



PR



HER2



H&E

